New hope for lymphoma patients: shorter chemo plus targeted pill

NCT ID NCT05551936

First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 10 times

Summary

This study tests a new combination of drugs for people with a slow-growing lymphoma that has a high tumor burden. Participants receive a targeted pill (tazemetostat) along with two standard chemotherapy drugs, but with fewer cycles of one chemo to reduce side effects. The goal is to see if this approach is safe and effective in controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • University of Illinois Cancer Center

    Chicago, Illinois, 60612, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53705, United States

Conditions

Explore the condition pages connected to this study.